ArticleProceedings of the National Academy of Sciences of the United States of America2006
Relevance and safety of telomerase for human tissue engineering.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Establishment of Stable Immortalized Human Choroidal Melanocytes for Ocular Research.Investigative ophthalmology & visual science · 2026Article
- Telomerase and telomeres in aging theory and chronographic aging theory (Review).Molecular medicine reports · 2020Review
- 3D Bioprinting and the Future of Surgery.Frontiers in surgery · 2020Review
- Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise.Cell stem cell · 2018Review
- Generation of an immortalized mesenchymal stem cell line producing a secreted biosensor protein for glucose monitoring.PloS one · 2017Article
- Defined conditions for the isolation and expansion of basal prostate progenitor cells of mouse and human origin.Stem cell reports · 2015Article
- The Challenge for Reconstructive Surgeons in the Twenty-First Century: Manufacturing Tissue-Engineered Solutions.Frontiers in surgery · 2015Article
- Smooth muscle and other cell sources for human blood vessel engineering.Cells, tissues, organs · 2012Review
- Tissue Engineering of Blood Vessels: Functional Requirements, Progress, and Future Challenges.Cardiovascular engineering and technology · 2011Article
- Molecular and functional effects of organismal ageing on smooth muscle cells derived from bone marrow mesenchymal stem cells.Cardiovascular research · 2010Article
- Novel utilization of serum in tissue decellularization.Tissue engineering. Part C, Methods · 2010Article
- Towards organ printing: engineering an intra-organ branched vascular tree.Expert opinion on biological therapy · 2010Review
- Nonviral gene delivery to mesenchymal stem cells using cationic liposomes for gene and cell therapy.Journal of biomedicine & biotechnology · 2010Article
- Utility of telomerase-pot1 fusion protein in vascular tissue engineering.Cell transplantation · 2010Article
- Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways.Circulation research · 2008Article
- Polymers to direct cell fate by controlling the microenvironment.Current opinion in biotechnology · 2007Review
- Cellular lifespan and regenerative medicine.Biomaterials · 2007Review
- Telomerase and the aging process.Experimental gerontology · 2007Review
- Improving cell therapy--experiments using transplanted telomerase-immortalized cells in immunodeficient mice.Mechanisms of ageing and development · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Tissue engineering holds the promise of replacing damaged or diseased tissues and organs. The use of autologous donor cells is often not feasible because of the limited replicative lifespan of cells, particularly those derived from elderly patients. Proliferative arrest can be overcome by the ectopic expression of telomerase via human telomerase reverse transcriptase (hTERT) gene transfection. To study the efficacy and safety of this potentially valuable technology, we used differentiated vascular smooth muscle cells (SMC) and vascular tissue engineering as a model system. Although we previously demonstrated that vessels engineered with telomerase-expressing SMC had improved mechanics over those grown with control cells, it is critical to assess the phenotypic impact of telomerase expression in donor cells, because telomerase up-regulation is observed in >95% of human malignancies. To study the impact of telomerase in tissue engineering, expression of hTERT was retrovirally induced in SMC from eight elderly patients and one young donor. In hTERT SMC, significant lifespan extension beyond that of control was achieved without population doubling time acceleration. Karyotype changes were seen in both control and hTERT SMC but were not clonal nor representative of cancerous change. hTERT cells also failed to show evidence of neoplastic transformation in functional assays of tumorigenicity. In addition, the impact of donor age on cellular behavior, particularly the synthetic capability of SMC, was not affected by hTERT expression. Hence, this tissue engineering model system highlights the impact of donor age on cellular synthetic function that appears to be independent of lifespan extension by hTERT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.